Adaptive trial designs in rheumatology: Report from the OMERACT special interest group

Tim Pickles, Rieke Alten, Maarten Boers, Vivian Bykerk, Jared Christensen, Robin Christensen, Hubert van Hoogstraten, Lee S. Simon, Lai-Shan Tam, Ernest H. Choy

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective. Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time. Methods. A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Results. Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint. Conclusion. The next step is to undertake a systematic review of adaptive designs used in early-phase
Original languageEnglish
Pages (from-to)1406-1408
Number of pages3
JournalJournal of Rheumatology
Volume46
Issue number10
DOIs
Publication statusPublished - Oct 2019

Cite this

Pickles, T., Alten, R., Boers, M., Bykerk, V., Christensen, J., Christensen, R., ... Choy, E. H. (2019). Adaptive trial designs in rheumatology: Report from the OMERACT special interest group. Journal of Rheumatology, 46(10), 1406-1408. https://doi.org/10.3899/jrheum.181054
Pickles, Tim ; Alten, Rieke ; Boers, Maarten ; Bykerk, Vivian ; Christensen, Jared ; Christensen, Robin ; van Hoogstraten, Hubert ; Simon, Lee S. ; Tam, Lai-Shan ; Choy, Ernest H. / Adaptive trial designs in rheumatology: Report from the OMERACT special interest group. In: Journal of Rheumatology. 2019 ; Vol. 46, No. 10. pp. 1406-1408.
@article{91f1e8382ff147ffbcd511820c0208da,
title = "Adaptive trial designs in rheumatology: Report from the OMERACT special interest group",
abstract = "Objective. Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time. Methods. A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Results. Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint. Conclusion. The next step is to undertake a systematic review of adaptive designs used in early-phase",
author = "Tim Pickles and Rieke Alten and Maarten Boers and Vivian Bykerk and Jared Christensen and Robin Christensen and {van Hoogstraten}, Hubert and Simon, {Lee S.} and Lai-Shan Tam and Choy, {Ernest H.}",
year = "2019",
month = "10",
doi = "10.3899/jrheum.181054",
language = "English",
volume = "46",
pages = "1406--1408",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

Pickles, T, Alten, R, Boers, M, Bykerk, V, Christensen, J, Christensen, R, van Hoogstraten, H, Simon, LS, Tam, L-S & Choy, EH 2019, 'Adaptive trial designs in rheumatology: Report from the OMERACT special interest group' Journal of Rheumatology, vol. 46, no. 10, pp. 1406-1408. https://doi.org/10.3899/jrheum.181054

Adaptive trial designs in rheumatology: Report from the OMERACT special interest group. / Pickles, Tim; Alten, Rieke; Boers, Maarten; Bykerk, Vivian; Christensen, Jared; Christensen, Robin; van Hoogstraten, Hubert; Simon, Lee S.; Tam, Lai-Shan; Choy, Ernest H.

In: Journal of Rheumatology, Vol. 46, No. 10, 10.2019, p. 1406-1408.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Adaptive trial designs in rheumatology: Report from the OMERACT special interest group

AU - Pickles, Tim

AU - Alten, Rieke

AU - Boers, Maarten

AU - Bykerk, Vivian

AU - Christensen, Jared

AU - Christensen, Robin

AU - van Hoogstraten, Hubert

AU - Simon, Lee S.

AU - Tam, Lai-Shan

AU - Choy, Ernest H.

PY - 2019/10

Y1 - 2019/10

N2 - Objective. Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time. Methods. A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Results. Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint. Conclusion. The next step is to undertake a systematic review of adaptive designs used in early-phase

AB - Objective. Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time. Methods. A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Results. Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint. Conclusion. The next step is to undertake a systematic review of adaptive designs used in early-phase

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072775404&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30770514

U2 - 10.3899/jrheum.181054

DO - 10.3899/jrheum.181054

M3 - Article

VL - 46

SP - 1406

EP - 1408

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -